Liquid oral formulations for tadalafil

US12186322B2 · kind B2 · utility

Assignee

• Liqmeds Worldwide Limited · GB

Inventors

• Jinal PANDYA · Shihi Village, IN
• Sandip P. Mehta · Ahmedabad, IN
• Manish Umrethia · Ahmedabad, IN
• Jayanta Kumar MANDAL · Ahmedabad, IN
• Hiren PANSURIYA · Ahmedabad, IN

Key dates

• Filing date: May 16, 2024
• Grant date: Jan 7, 2025
• Expiry date: May 16, 2044

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K47/10
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure is directed to pharmaceutical compositions comprising a PDE V inhibitor and one or more pharmaceutical excipients or additives wherein the pharmaceutical compositions are in the form of liquid pharmaceutical compositions. The pharmaceutical compositions of the present disclosure are useful for the treatment of diseases or conditions which are treatable by administration of PDE V inhibitor drug such as pulmonary arterial hypertension, erectile dysfunction, etc.